Relieving Chronic Itch: Oral Medication (CIPS)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02909569 |
Recruitment Status :
Withdrawn
(Contract could not be agreed on.)
First Posted : September 21, 2016
Last Update Posted : May 13, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Pruritis | Drug: INCB039110 | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 0 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Relieving Chronic Itch : Oral Medication |
Estimated Study Start Date : | August 2018 |
Actual Primary Completion Date : | October 9, 2018 |
Actual Study Completion Date : | October 9, 2018 |
Arm | Intervention/treatment |
---|---|
Experimental: INCB039110
INCN039110 400 mg QD for 20 weeks. Subjects without clinical response after four weeks will increase to 600mg QD.
|
Drug: INCB039110
All subjects will receive 400 mg PO QD for 12 weeks. If no clinical response after four weeks, dose will be increased to 600 mg PO QD. Total duration of subject participation will be six study visit over 20 weeks. |
- Numerical Rating Scale (NRS) itch score [ Time Frame: Baseline to 12 weeks ]Absolute change from Baseline NRS itch score to week 12

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Male and non-pregnant, non-lactating female subjects aged 18 years or older
- Diagnosed with chronic idiopathic pruritus (CIP) with an NRS Itch Score of ≥ 7 at both Screening and Baseline
- Diagnosis of CIP for at least 6 weeks prior to screening
- Willingness to avoid pregnancy or fathering of children
- Ability and willingness to provide written informed consent
- Willing and able to comply with all study requirements and restrictions
- Willing to not participate in any other interventional trial for the duration of their participation
- Subjects must be in good health as determined by medical history, physical examination, electrocardiogram, clinical laboratory tests and vital signs
- Failure of a course 2-week course of treatment with topical triamcinolone 0.1% ointment BID
- Histopathological demonstration of skin dermal edema, eosinophils, mast cell activation or lymphocytic infiltration
Exclusion Criteria:
- Chronic pruritus due to a defined primary dermatologic disorder (e.g., atopic dermatitis, psoriasis, etc.)
- Patients with a prior diagnosis of excoriation disorder
- Use of topical treatments for CIP (other than bland emollients) within 1 week of baseline
- Systemic immunosuppressive or immunomodulating drugs (eg, oral or injectable corticosteroids, methotrexate, cyclosporine, mycophenolat mofetil, azathioprine) within 4 weeks of baseline
-
Subjects with cytopenias at screening, defined as:
- Leukocytes < 3 × 109/L
- Neutrophils < lower limit of normal
- Lymphocytes < 0.8 × 109/L
- Hemoglobin < 10 g/dL
- Platelets < 100 × 109/L
- Unwilling or unable to follow medication restrictions or unwilling or unable to sufficiently washout from use of restricted medication
- Use of any prohibited medications (see Section 5.8) within 14 days or 5 half-lives (whichever is longer) of the baseline visit
-
Current clinically significant cardiovascular, respiratory, neurologic, hepatic, hematopoietic, renal gastrointestinal, endocrine or metabolic dysfunction unless currently controlled and stable, including (but not limited to) the following:
- Positive for hepatitis C antibody test (anti-HCAbF) with detectable RNA
- Positive for hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb);
- Positive for HIV (DUO test, p24 antigen)
- Active malignancy
- Subjects with a history of malignancy, except for the following adequately treated, nonmetastatic malignancies: basal cell skin cancer, squamous cell carcinomas of the skin, or in situ cervical cancer
- History (including family history) or current evidence of congenital long QT syndrome or known acquired QT prolongation
- Exposure to any investigational medication, including placebo, within 60 days of the Baseline Visit
- History of intolerance and/or hypersensitivity to medications similar to INCB039110 (e.g., Xeljanz)
- Participation in a previous INCB39110 trial
-
Subjects with severely impaired liver function (Child-Pugh Class C) or end-stage renal disease on dialysis or at least 1 of the following:
- Serum creatinine > 1.5 mg/dL;
- Alanine aminotransferase or aspartate aminotransferase ≥ 1.5 × upper limit of normal
- Anyone affiliated with the site or sponsor and/or anyone who may consent under duress
- Any other sound medical reason as determined by the Investigator including any condition which may lead to an unfavorable risk-benefit of study participation, may interfere with study compliance or may confound study results
- Subjects taking potent systemic CYP3A4 inhibitors or fluconazole within 2 weeks or 5 half-lives, whichever is longer, before the baseline visit
- Subjects who have previously received JAK inhibitors, systemic or topical (e.g. ruxolitinib, tofacitinib, baricitinib, filgotinib, lestaurtinib and pacritinib)
- Women who were pregnant or breastfeeding within 4 months before screening.
- Current or recent history (< 30 days before screening and/or < 45 days before randomization) of a clinically meaningful bacterial, fungal, parasitic, or mycobacterial infection
- Clinically significant or uncontrolled cardiac disease, including unstable angina, acute myocardial infarction within 6 months from Day 1 of study drug administration, New York Heart Association Class III or IV congestive heart failure, and arrhythmia requiring therapy or uncontrolled hypertension (blood pressure > 150/90 mmHg) unless approved by medical monitor/sponsor
- History of alcoholism or drug addiction within 1 year before screening, or current alcohol or drug use that, in the opinion of the investigator, will interfere with the subject's ability to comply with the administration schedule and study assessments
- Subjects who have received systemic chemotherapy at any time
- Subjects who anticipate receiving a live or live-attenuated vaccination from screening through the final follow-up visit
-
Subjects who, in the opinion of the investigator, are unable or unlikely to comply with the administration schedule and study evaluations
-

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02909569
Principal Investigator: | Brian Kim, MD/MTR | Washington University School of Medicine |
Responsible Party: | Washington University School of Medicine |
ClinicalTrials.gov Identifier: | NCT02909569 |
Other Study ID Numbers: |
CIP9110 |
First Posted: | September 21, 2016 Key Record Dates |
Last Update Posted: | May 13, 2019 |
Last Verified: | May 2019 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Pruritus Skin Diseases Skin Manifestations |